Novo Nordisk's next act in the obesity space isn't another semaglutide variant — it's CagriSema, a combination of semaglutide and the amylin analog cagrilintide. In Phase 3 trials, CagriSema delivered 22.7% weight loss at 68 weeks, putting it in direct competition with Eli Lilly's Zepbound. Here's what you need to know about the drug, the data, and the timeline.
What Is CagriSema?
CagriSema is a fixed-dose combination of two active ingredients delivered as a once-weekly subcutaneous injection:
- Cagrilintide 2.4 mg — a long-acting amylin analog
- Semaglutide 2.4 mg — the same GLP-1 receptor agonist found in Wegovy
The logic: semaglutide and cagrilintide work through different but complementary pathways. Semaglutide activates the GLP-1 receptor, reducing appetite and slowing gastric emptying. Cagrilintide mimics amylin, a pancreatic hormone that promotes satiety, slows nutrient absorption, and suppresses glucagon secretion. Together, they produce greater weight loss than either component alone.
The Clinical Data
The headline number comes from the REDEFINE-1 Phase 3 trial, which enrolled approximately 3,400 adults with obesity or overweight with at least one weight-related comorbidity:
- CagriSema group: 22.7% mean body weight reduction at 68 weeks
- Semaglutide 2.4 mg alone: 15.8% weight loss
- Cagrilintide 2.4 mg alone: 8.0% weight loss
- Placebo: 2.2% weight loss
That 22.7% figure is significant because it demonstrates that adding cagrilintide to semaglutide provides a meaningful boost — nearly 7 percentage points above semaglutide alone. For a patient weighing 250 lbs, that's the difference between losing roughly 40 lbs (semaglutide) vs. 57 lbs (CagriSema).
Side Effects in Trials
The side effect profile was broadly similar to semaglutide alone, with GI symptoms being the most common:
- Nausea: ~40% (vs ~32% for semaglutide alone)
- Vomiting: ~17% (vs ~13%)
- Diarrhea: ~22% (vs ~19%)
- Constipation: ~14% (vs ~12%)
The slightly higher GI rates are expected with a dual-mechanism drug. Most events were mild to moderate and concentrated during the titration period.
How CagriSema Compares to Current Options
| Medication | Mechanism | Weight Loss | Form | Estimated Cost |
|---|---|---|---|---|
| CagriSema | GLP-1 + amylin | 22.7% | Weekly injection | $1,500+/mo (estimated) |
| Zepbound | GLP-1 + GIP | 22.5% | Weekly injection | $299–549/mo (LillyDirect) |
| Wegovy | GLP-1 | 15.0% | Weekly injection | $1,349/mo list |
| Foundayo | GLP-1 (small molecule) | 12.4% | Daily oral pill | $149–349/mo (LillyDirect) |
CagriSema's 22.7% is essentially comparable to Zepbound's 22.5% — a statistical dead heat. The differentiator will likely come down to cost, tolerability, and insurance coverage rather than raw efficacy. For a detailed look at currently available options, see our Foundayo vs Wegovy comparison.
FDA Timeline
Novo Nordisk filed its New Drug Application (NDA) on December 18, 2025. Under the standard 10-month review clock, the FDA's target action date falls around October 2026. Key milestones:
- December 2025: NDA submitted
- Q1 2026: FDA accepts filing, confirms PDUFA date
- ~October 2026: Expected FDA decision (approval, complete response letter, or request for additional data)
- Q1 2027: Estimated commercial launch if approved on first cycle
Manufacturing scale-up is already underway at Novo Nordisk's facilities, suggesting confidence in a first-cycle approval.
Expected Pricing
Novo Nordisk has not announced pricing for CagriSema, but analysts expect it to command a premium — likely $1,500 or more per month at list price. The justification: it's a combination product delivering best-in-class efficacy. Whether payers will cover it at that price, especially when Zepbound delivers comparable results at lower self-pay cost, remains to be seen.
For patients concerned about cost, Foundayo at $149/month remains the most affordable branded GLP-1 option, though with lower peak weight loss.
Who Is CagriSema Best For?
Based on the trial data and likely market positioning, CagriSema will be most relevant for:
- Patients who plateau on semaglutide alone. If you've maxed out on Wegovy or Ozempic and want more weight loss, CagriSema's dual mechanism may break through that plateau
- Patients who need maximum weight loss. At 22.7%, CagriSema is among the highest-efficacy options available (matched only by Zepbound)
- Patients with good insurance coverage. Given the expected premium price, CagriSema will make the most financial sense for those with robust pharmaceutical coverage
Patients who are currently happy with their results on Wegovy, Zepbound, or Foundayo have no reason to switch. CagriSema fills a niche for those seeking maximum efficacy and willing to pay for it.
Bottom Line
CagriSema is the real deal — 22.7% weight loss that rivals Zepbound, built on a novel amylin + GLP-1 combination mechanism. If the FDA approves it on schedule in October 2026, it should be available by early 2027. But it won't be cheap, and its efficacy advantage over Zepbound is marginal at best. For most patients, the question won't be "Is CagriSema better?" but "Is it worth the premium?" We'll update this guide as the FDA review progresses and pricing details emerge.
Sources
- Novo Nordisk. "REDEFINE-1 Phase 3 Trial Results." Presented at ObesityWeek 2025.
- Novo Nordisk. "CagriSema NDA Submission." Press release, December 18, 2025.
- Wilding JPH et al. "Cagrilintide and Semaglutide for Obesity." NEJM. 2025.
- FDA. PDUFA Date Tracker. 2026.